Figure 2From: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumorsA 67-year old female patient diagnosed with MBC who had experienced treatment failure after 2 chemotheraphy and 2 hormonal regimens, but did not receive trastuzumab. She had confirmed PR at the 1500Â mg BID dose level of AST1306, but withdrew from the study after 9Â months due to continuous grade 2 diarrhea. A) CT imaging of the metastatic lesion prior to starting therapy, and B) shows the response to AST1306 two cycles after starting therapy. C and D shows continued response three and ten cycles after starting therapy.Back to article page